These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 2256481

  • 1. Focus on proteinuria.
    Glassock RJ.
    Am J Nephrol; 1990; 10 Suppl 1():88-93. PubMed ID: 2256481
    [Abstract] [Full Text] [Related]

  • 2. The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility.
    Remuzzi A, Remuzzi G.
    Semin Nephrol; 1995 May; 15(3):236-43. PubMed ID: 7631050
    [Abstract] [Full Text] [Related]

  • 3. Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake.
    Rodrigo R, Bravo I, Pino M.
    Nutr Rev; 1996 Nov; 54(11 Pt 1):337-47. PubMed ID: 9110562
    [Abstract] [Full Text] [Related]

  • 4. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome?
    de Jong PE, Anderson S, de Zeeuw D.
    J Am Soc Nephrol; 1993 Jan; 3(7):1333-41. PubMed ID: 8439644
    [Abstract] [Full Text] [Related]

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 6. Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease.
    Navis G, Buter H, de Jong PE, Dullaart RP, de Zeeuw D.
    Contrib Nephrol; 1997 Nov 09; 120():88-96. PubMed ID: 9257051
    [No Abstract] [Full Text] [Related]

  • 7. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C, Seidl U, Reinecke A, Riester U, Graf K, Schultheiss HP, Hilgenfeldt U, Unger T.
    Int Immunopharmacol; 2003 Mar 09; 3(3):335-44. PubMed ID: 12639811
    [Abstract] [Full Text] [Related]

  • 8. Proteinuria in Frasier syndrome.
    Peco-Antić A, Ozaltin F, Parezanović V, Milosevski-Lomić G, Zdravković V.
    Srp Arh Celok Lek; 2013 Mar 09; 141(9-10):685-8. PubMed ID: 24364235
    [Abstract] [Full Text] [Related]

  • 9. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
    Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS, AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease.
    Kidney Int; 2001 Sep 09; 60(3):1131-40. PubMed ID: 11532109
    [Abstract] [Full Text] [Related]

  • 10. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy.
    Gansevoort RT, Heeg JE, Vriesendorp R, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1992 Sep 09; 7 Suppl 1():91-6. PubMed ID: 1337189
    [Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb 09; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 12. Symptomatic treatment of nephrotic syndrome.
    McLigeyo SO.
    East Afr Med J; 1993 Jan 09; 70(1):1-2. PubMed ID: 8513718
    [No Abstract] [Full Text] [Related]

  • 13. Proteinuria: clinical signficance and basis for therapy.
    Woo KT, Lau YK.
    Singapore Med J; 2001 Aug 09; 42(8):385-9. PubMed ID: 11764058
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
    Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G.
    Exp Nephrol; 1996 Aug 09; 4(1):19-25. PubMed ID: 8788596
    [Abstract] [Full Text] [Related]

  • 15. Hormonal modulation of proteinuria in the nephrotic syndrome.
    Hutchison FN.
    Am J Nephrol; 1993 Aug 09; 13(5):337-46. PubMed ID: 8116686
    [Abstract] [Full Text] [Related]

  • 16. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct 09; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T, Pohl M, Misselwitz J, John U.
    Kidney Blood Press Res; 2009 Oct 09; 32(6):440-4. PubMed ID: 20016211
    [Abstract] [Full Text] [Related]

  • 18. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL.
    Clin J Am Soc Nephrol; 2008 Jan 09; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [Abstract] [Full Text] [Related]

  • 19. [Responsible genes for proteinuria and concept of the treatment for proteinuria].
    Shimizu F.
    Nihon Rinsho; 2004 Oct 09; 62(10):1800-4. PubMed ID: 15500121
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of antihypertensive agents on proteinuria and renal function.
    Maki DD, Ma JZ, Louis TA, Kasiske BL.
    Arch Intern Med; 1995 May 22; 155(10):1073-80. PubMed ID: 7748051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.